Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
Furthermore, when larger group testing occurs, this allows researchers to identify and ensure that any improvements resulting from the intervention occurs for as many people as possible and are not just occurring in one individual.
Ahead of the J.P. Morgan Health Conference in San Francisco in January 2023, Australian Health Journal met with Clinials CEO & Founder Maree Beare about developing the next generation recruitment platform and digital marketing service for clinical research. Maree talks about the reasons why clinical trials can fail and the importance of bringing participants much more closer to researchers.
With this need, the Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
Supporting CRO’s, sites and sponsors, the Clinials platform uses AI to convert complex trial protocol into plain language and pre-screening questions. This gives researchers the tools to communicate with their participants meaningfully. The plain language text can be used in a variety of situations like researcher led advertising, landing pages and plain language summaries.
You Might also like
-
Cardiovascular Disease Risk Guidance and Calculator get long overdue update
Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.
-
Belonging in a medical device company
Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
-
From paediatric nursing to leadership & private hospital general management
With over 20 years of experience in the Australian and international healthcare sectors, Georgia Banks is a dedicated and results-driven health professional with a proven track record in clinical, financial, human resources, and strategic management. Passionate about delivering high-quality patient care, Georgia possesses an authentic leadership style that fosters engagement, collaboration, and continuous improvement.
Currently serving as General Manager at Hobart Private Hospital within Healthscope, Georgia has been instrumental in driving operational excellence, enhancing patient experience, and supporting staff development. Her leadership has played a key role in aligning hospital services with strategic priorities while fostering a culture of accountability and innovation.